Thermo Fisher Scientific Inc. (TMO) on Decifer

Why it ranks here

• Sales are growing about 5% a year, faster than 19 in 100 companies we measure.
• It keeps about 14 cents of every sales dollar as cash, safer than 74 in 100 companies we measure.
• It earns about 8% a year on the money put into the business, better than 46 in 100 companies we measure.
• It costs about 36 times its yearly profit; the middle of its industry is 38. Cheaper than 57 in 100 companies we measure, against their own industries.

The current read

The evidence on TMO points in two directions at once: the intelligence feed flags this name as connected to what is moving markets now, while price is lagging the market story behind this name, a sign the connection is not paying off. Until one side gives way, treat the picture as unresolved rather than a clean story.

Themes

• Genomic Medicine & Precision Diagnostics: The collapsing cost of DNA/RNA sequencing and validation of genomic classifiers is moving clinical practice toward routine molecular diagnostics and companion testing.

Read the full TMO research brief · See all quality rankings

Intelligence data powered by Decifer. Not financial advice. For informational purposes only.